Evofem Biosciences (EVFM) Tops Q4 EPS by 2c

Evofem Biosciences (NASDAQ: EVFM) reported Q4 EPS of ($0.27), $0.02 better than the analyst estimate of ($0.29).

"The Evofem team's exceptional execution in 2019 laid the groundwork for what will be a transformative year for the Company," said Saundra Pelletier, Chief Executive Officer, Evofem Biosciences. "We are rapidly approaching the established FDA PDUFA date for our innovative, hormone-free, investigational contraceptive gel, which we are thrilled to share is now branded as Phexxi.

"We remain focused on establishing a best-in-class sales force, initiating pre-commercial activities and continuing to disseminate compelling new data via conferences and publications. We are also preparing for other important catalysts that have the potential to drive future growth, including an end-of-phase 2 meeting with the FDA to discuss the potential path forward for EVO100 for the prevention of chlamydia and gonorrhea."

For earnings history and earnings-related data on Evofem Biosciences (EVFM) click here.

You May Also Be Interested In

• Lucid reports Q2 output, names new CFO and five other leaders
• SOL Strategies reports June operations after Houdini Swap acquisition
• Rivian raises 2026 delivery outlook after Q2 results top guidance